Want to see GDTC full AI Analyst Report?
Top Page
CytoMed Therapeutics Limited
(NASDAQ:GDTC)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.79
▼(-17.16% Downside)
Action:Reiterated
Date:07/28/26
The score is driven primarily by weak financial performance—persistent losses and ongoing cash burn—combined with bearish technicals (trading below key moving averages). Improved balance sheet leverage is a mitigating factor, while valuation signals are limited due to the negative P/E and lack of dividend data.
Positive Factors
Improved Leverage
The material reduction in leverage improves financial flexibility compared with the company’s earlier capital structure. Lower debt exposure can reduce balance-sheet strain and preserve more room to fund development, although profitability remains unresolved.
Negative Factors
Persistent Unprofitability
Persistent operating and net losses show that the current revenue base does not cover the company’s cost structure. Negative gross profit in 2025 further suggests weak economics, leaving profitability dependent on meaningful business improvement or successful pipeline progress.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Leverage
The material reduction in leverage improves financial flexibility compared with the company’s earlier capital structure. Lower debt exposure can reduce balance-sheet strain and preserve more room to fund development, although profitability remains unresolved.
Read all positive factors
CytoMed Therapeutics Limited (GDTC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.60M
Dividend YieldN/A
Average Volume (3M)15.74K
Price to Earnings (P/E)―
Beta (1Y)0.03
Revenue Growth49.09%
EPS Growth3.91%
CountryUS
Employees42
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,832,835
10 Day Avg. Volume22,478
30 Day Avg. Volume15,737
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)3.07
Price to Sales (P/S)62.86
P/FCF Ratio-4.56
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue22.22
Enterprise Value/Gross Profit-15.53
Enterprise Value/Ebitda-2.32
Forecast
1Y Price Target
$4.16Price Target Upside337.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CytoMed Therapeutics Limited Business Overview & Revenue Model
Company Description
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignan...
How the Company Makes Money
null...
CytoMed Therapeutics Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 530.70K | 319.20K | 69.50K | 509.13K | 365.60K | 0.00 |
| Gross Profit | -759.17K | ― | 52.38K | 505.39K | -109.04K | 110.29K |
| EBITDA | -5.08M | -4.12M | -1.78M | -3.61M | -1.89M | -1.56M |
| Net Income | -4.37M | -3.92M | -2.52M | -4.14M | -3.06M | -2.07M |
Balance Sheet | ||||||
| Total Assets | 7.01M | 7.98M | 10.07M | 12.40M | 5.25M | 6.10M |
| Cash, Cash Equivalents and Short-Term Investments | 1.46M | 2.10M | 4.97M | 9.02M | 1.59M | 2.53M |
| Total Debt | 453.76K | 482.56K | 463.15K | 449.25K | 4.24M | 3.27M |
| Total Liabilities | 1.61M | 1.13M | 1.02M | 1.13M | 4.66M | 3.50M |
| Stockholders Equity | 4.97M | 6.54M | 8.96M | 11.28M | 589.71K | 2.60M |
Cash Flow | ||||||
| Free Cash Flow | -5.39M | -4.40M | -4.11M | -3.60M | -1.88M | -2.30M |
| Operating Cash Flow | -4.76M | -3.70M | -2.71M | -3.54M | -1.40M | -1.72M |
| Investing Cash Flow | 1.67M | 929.28K | 1.13M | -2.73M | -475.51K | -825.59K |
| Financing Cash Flow | 1.05M | 208.65K | -64.88K | 10.92M | 968.35K | 4.18M |
CytoMed Therapeutics Limited Technical Analysis
Negative
0.95
Price Trends
0.90
Negative
0.98
Negative
1.01
Negative
Market Momentum
>-0.01
Positive
42.20
Neutral
42.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GDTC, the sentiment is Negative. The current price of 0.95 is above the 20-day moving average (MA) of 0.91, above the 50-day MA of 0.90, and below the 200-day MA of 1.01, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.20 is Neutral, neither overbought nor oversold. The STOCH value of 42.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GDTC.
CytoMed Therapeutics Limited Risk Analysis
CytoMed Therapeutics Limited disclosed 106 risk factors in its most recent earnings report. CytoMed Therapeutics Limited reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CytoMed Therapeutics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $14.95M | >-0.01 | -147.45% | ― | ― | ― | |
46 Neutral | $14.64M | -0.40 | -218.59% | ― | ― | 38.14% | |
44 Neutral | $9.60M | -2.26 | -87.20% | ― | 49.09% | 3.91% | |
44 Neutral | $9.55M | -0.36 | -209.67% | ― | ― | 79.26% |
* Healthcare Sector Average
GDTC
CytoMed Therapeutics Limited
0.81
-1.12
-57.98%
AKTX
Akari Therapeutics
8.54
-29.14
-77.33%
MTVA
MetaVia
1.45
-9.45
-86.70%
PASG
Passage Bio
4.55
-4.14
-47.64%
KAPA
Kairos Pharma, Ltd.
0.83
-7.64
-90.18%
CytoMed Therapeutics Limited Corporate Events
CytoMed Therapeutics Posts Narrower Interim Loss in June 2026 SEC Filing
Sep 30, 2026
CytoMed Therapeutics Limited has filed a Form 6-K with the U.S. Securities and Exchange Commission for the financial period ended June 30, 2026, furnishing unaudited interim condensed consolidated financial statements and management’s discus...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.